Scientists test how cancer drug works in different patients
NCT ID NCT02680795
Summary
This early-stage study aimed to understand how the body processes the cancer drug belinostat in patients with advanced solid tumors or blood cancers that have returned or stopped responding to treatment. Researchers specifically looked at how different genetic backgrounds affect drug levels in the blood and urine. The study involved 17 patients who received the drug for 5 days and was focused on safety and measuring drug processing, not on testing how well it treats cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gabrail Cancer Center Research
Canton, Ohio, 44718, United States
-
John Wayne Cancer Institute @ Providence Saint John's Health Center
Santa Monica, California, 90404, United States
-
The Oncology Institute of Hope and Innovation
Whittier, California, 90603, United States
Conditions
Explore the condition pages connected to this study.